Efficacy and Safety of the Anti-Tissue Factor Pathway Inhibitor Marstacimab in Participants with Severe Hemophilia without Inhibitors: Results from the Phase 3 Basis Trial-MedSci.cn

Efficacy and Safety of the Anti-Tissue Factor Pathway Inhibitor Marstacimab in Participants with Severe Hemophilia without Inhibitors: Results from the Phase 3 Basis Trial

Matino, D; Acharya, S; Palladino, A; Hwang, E; McDonald, R; Taylor, CT; Teeter, J

BLOOD, 2023; 142 ():

科室
- - 订阅+
  - 更多科室
工具
服务